#Viral Hepatitis


Bangladesh - Malaysia aims to become Hepatitis C treatment hub

Being the first country in the world to be given conditional approval for combining ravidasvir with sofosbuvir to treat Hepatitis C, Malaysia is poised to offer access to an affordable and efficacious treatment solution for those infected with the virus. Speaking at the launch of Malaysia as the Hepatitis C...
Picture for Bangladesh - Malaysia aims to become Hepatitis C treatment hub

Hepatitis A alert for thousands of Starbucks customers

Health officials in Camden County, New Jersey are urging people to get vaccinated against Hepatitis A after a Starbucks employee tested positive for the virus. Thousands of customers may have been infected. The county health department reported last week that a food handler employed at a Starbucks restaurant in Gloucester...
Picture for Hepatitis A alert for thousands of Starbucks customers

State releases long-awaited plan for eliminating hepatitis C

More than two years after the New York State Hepatitis C Elimination Task Force last met, the state Department of Health has released a report based on their recommendations. The New York State Hepatitis C Elimination Plan, which is available below, is supposed to serve as a roadmap for the state to eliminate hepatitis c as a public health problem. The report recommends creating a two-year pilot program to study the “feasibility and effectiveness of a medically supervised program where patients self-administer prescription pharmaceutical opioids” and – in recognition of the opioid epidemic as a public health emergency – the availability of “safer injection facilities across” New York.

Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

Ascletis Pharma Inc. (Ascletis) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announced that Ascletis’ subsidiary and Suzhou Alphamab have entered into an exclusive worldwide licensing agreement (excluding Greater China) for ASC22 (Envafolimab) to treat viral diseases, including Hepatitis B. According to the press release, ASC22, also known as KN035, is one of the first subcutaneously-injected PD-L1 antibodies. An oncology biologic license application was submitted to the Chinese National Medicine Products Administration in December 2020, and other oncology indications are currently under development by Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Enanta Pharma (ENTA) is discontinuing development of EDP-721

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it is discontinuing development of EDP-721, an oral HBV RNA destabilizer, based on emerging safety observations in the single ascending dose part of a Phase 1 study in healthy volunteers.

Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B

Host immune response and chronic inflammation associated with chronic hepatitis B virus (HBV) infection play a key role in the pathogenesis of liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). We sampled 175 HCC, 117 cirrhotic and 165 non-cirrhotic controls from a prospective cohort study of chronically HBV-infected individuals. Multivariable polytomous logistic regression and canonical discriminant analysis (CDA) were used to compare baseline plasma levels for 102 markers in individuals who developed cirrhosis vs. controls and those who developed HCC vs. cirrhosis. Leave-one-out cross validation was used to generate receiver operating characteristic curves to compare the predictive ability of marker groups. After multivariable adjustment, HGF (Q4v1OR: 3.74; p-trend"‰="‰0.0001), SLAMF1 (Q4v1OR: 4.07; p-trend"‰="‰0.0001), CSF1 (Q4v1OR: 3.00; p-trend"‰="‰0.002), uPA (Q4v1OR: 3.36; p-trend"‰="‰0.002), IL-8 (Q4v1OR: 2.83; p-trend"‰="‰0.004), and OPG (Q4v1OR: 2.44; p-trend"‰="‰0.005) were all found to be associated with cirrhosis development compared to controls; these markers predicted cirrhosis with 69% accuracy. CDA analysis identified a nine marker model capable of predicting cirrhosis development with 79% accuracy. No markers were significantly different between HCC and cirrhotic participants. In this study, we assessed immunologic markers in relation to liver disease in chronically-HBV infected individuals. While validation in required, these findings highlight the importance of immunologic processes in HBV-related cirrhosis.

Hepatitis C Treatment Has Declined Since 2015

After reaching a peak in 2015, the number of people treated with direct-acting antiviral therapy for hepatitis C has steadily declined, reaching a low mark in 2020, according to new data from the Centers for Disease Control and Prevention (CDC) presented this week at The Liver Meeting. Although about 120,000...

Arrowhead Collaborator Presents Phase 2b Clinical Data From REEF-1 Study In Patients With Chronic Hepatitis B Infection

Arrowhead Pharmaceuticals Inc. (ARWR) - Get Arrowhead Pharmaceuticals, Inc. Report collaborator Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB). The data were presented in a late breaking oral presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).

discover that 7 out of 10 diagnosed patients do not have medical follow-up

Experts from Clinic Hospital today present the preliminary results of an initiative called “Relinking to the medical care of patients with hepatitis C”, which consists of the review of the file of clinical records of the Division of Hepatology to reconnect with patients those who had been diagnosed with the disease, but did not follow the path until they were cured. This will take place within the framework of the 4th University Symposium of Gastroenterology and Hepatology, organized by the Medical Association of the Hospital de Clínicas.
MedPage Today

Fewer Hepatitis C Patients Seeking Treatment of Late

The number of people with hepatitis C virus (HCV) treated with direct-acting antiviral agents (DAAs) dropped sharply in 2020, accelerating a decline that began in 2015, CDC researchers found. While 843,362 individuals from 2014-2020 were estimated to receive DAAs for HCV, only 83,740 initiated DAA treatment in 2020, down from...

Evaluation of COVID-19 testing quality underway in Kyrgyzstan

AKIPRESS.COM - The quality of laboratory testing for socially important infections, COVID-19 among them, is evaluated by the National Center for Laboratory Testing Control. Socially important infections include viral hepatitis, HIV, urogenital infections, brucellosis, etc. The specialists of the Center visit regions and evaluate quality of testing by laboratories for...